Polonsky WH, Henry RR. Poor remedy adherence in sort 2 diabetes: recognizing the scope of the issue and its key contributors. Affected person Choose Adherence. 2016;10:1299–307.
Loretz B, et al. Oral gene supply: methods to enhance stability of pDNA in the direction of intestinal digestion. J Drug Goal. 2006;14(5):311–9.
Lehr C-M, et al. An estimate of turnover time of intestinal mucus gel layer within the rat in situ loop. Int J Pharm. 1991;70(3):235–40.
Gardner ML. Gastrointestinal absorption of intact proteins. Annu Rev Nutr. 1988;8:329–50.
Corfield AP, et al. Mucins within the gastrointestinal tract in well being and illness. Entrance Biosci. 2001;6:D1321–57.
Fallingborg J, et al. pH-profile and regional transit occasions of the traditional intestine measured by a radiotelemetry gadget. Aliment Pharmacol Ther. 1989;3(6):605–13.
Perry SL, McClements DJ. Current advances in encapsulation, safety, and oral supply of bioactive proteins and peptides utilizing colloidal methods. Molecules. 2020;25(5):1161.
Caffarel-Salvador E, et al. Oral supply of biologics utilizing drug-device combos. Curr Opin Pharmacol. 2017;36:8–13.
Marasini N, Skwarczynski M, Toth I. Oral supply of nanoparticle-based vaccines. Skilled Rev Vaccines. 2014;13(11):1361–76.
Yoshida M, et al. Complexation hydrogels as potential carriers in oral vaccine supply methods. Eur J Pharm Biopharm. 2017;112:138–42.
des Rieux A, et al. Nanoparticles as potential oral supply methods of proteins and vaccines: a mechanistic strategy. J Management Launch. 2006;116(1):1–27.
McClements DJ. Encapsulation, safety, and supply of bioactive proteins and peptides utilizing nanoparticle and microparticle methods: a overview. Adv Colloid Interface Sci. 2018;253:1–22.
Gabor F, et al. The lectin-cell interplay and its implications to intestinal lectin-mediated drug supply. Adv Drug Deliv Rev. 2004;56(4):459–80.
Ibrahim YHY, et al. Overview of just lately used strategies and supplies to enhance the effectivity of orally administered proteins/peptides. Daru. 2019;28:403–16.
Musika J, Chudapongse N. Growth of lipid-based nanocarriers for rising gastrointestinal absorption of Lupinifolin. Planta Med. 2020;86(5):364–72.
Dumont C, et al. In-vitro analysis of stable lipid nanoparticles: capacity to encapsulate, launch and guarantee efficient safety of peptides within the gastrointestinal tract. Int J Pharm. 2019;565:409–18.
Kurd M, et al. Oral supply of indinavir utilizing mPEG-PCL nanoparticles: preparation, optimization, mobile uptake, transport and pharmacokinetic analysis. Artif Cells Nanomed Biotechnol. 2019;47(1):2123–33.
Bransil R, Turner BS. Mucin construction, aggregation, physiological features and biomedical purposes. Curr Opin Colloid Interface Sci. 2006;11(2–3):164–70.
Offner GD, et al. The amino-terminal sequence of MUC5B comprises conserved multifunctional D domains: implications for tissue-specific mucin features. Biochem Biophys Res Commun. 1998;251(1):350–5.
de Bolos C, Actual FX, Lopez-Ferrer A. Regulation of mucin and glycoconjugate expression: from regular epithelium to gastric tumors. Entrance Biosci. 2001;6:d1256–63.
Schneider H, et al. Research of mucin turnover within the small gut by in vivo labeling. Sci Rep. 2018;8(1):1–11.
Johansson MEV, et al. The interior of the 2 Muc2 mucin-dependent mucus layers in colon is devoid of micro organism. Proc Natl Acad Sci. 2008;105(39):15064–9.
Arul GS, et al. Mucin gene expression in Barrett’s oesophagus: an in situ hybridisation and immunohistochemical research. Intestine. 2000;47(6):753–61.
Ho SB, et al. The adherent gastric mucous layer consists of alternating layers of MUC5AC and MUC6 mucin proteins. Dig Dis Sci. 2004;49(10):1598–606.
Gustafsson JK, et al. An ex vivo technique for learning mucus formation, properties, and thickness in human colonic biopsies and mouse small and huge intestinal explants. Am J Physiol Gastrointest Liver Physiol. 2012;302(4):G430–8.
Johansson MEV, Sjövall H, Hansson GC. The gastrointestinal mucus system in well being and illness. Nat Rev Gastroenterol Hepatol. 2013;10(6):352–61.
Ouellette AJ. Paneth cells and innate mucosal immunity. Curr Opin Gastroenterol. 2010;26(6):547–53.
Vaishnava S, et al. The antibacterial lectin RegIIIγ promotes the spatial segregation of microbiota and host within the gut. Science. 2011;334(6053):255–8.
Chu H, et al. Human α-defensin 6 promotes mucosal innate immunity via self-assembled peptide nanonets. Science. 2012;337(6093):477–81.
Johansson MEV, Hansson GC. Protecting micro organism at a distance. Science. 2011;334(6053):182–3.
Meaney C, O’Driscoll C. Mucus as a barrier to the permeability of hydrophilic and lipophilic compounds within the absence and presence of sodium taurocholate micellar methods utilizing cell tradition fashions. Eur J Pharm Sci. 1999;8(3):167–75.
Dekker J, et al. The MUC household: an obituary. Traits Biochem Sci. 2002;27(3):126–31.
Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev. 2009;61(2):75–85.
Verdugo P. Goblet cells secretion and mucogenesis. Annu Rev Physiol. 1990;52(1):157–76.
Shogren R, Gerken TA, Jentoft N. Function of glycosylation on the conformation and chain dimensions of O-linked glycoproteins: light-scattering research of ovine submaxillary mucin. Biochemistry. 1989;28(13):5525–36.
Sheehan JK, Oates Okay, Carlstedt I. Electron microscopy of cervical, gastric and bronchial mucus glycoproteins. Biochem J. 1986;239(1):147–53.
Herrmann A, et al. Research on the “insoluble” glycoprotein complicated from human colon Identification of reduction-insensitive MUC2 oligomers and C-terminal cleavage. J Biol Chem. 1999;274(22):15828–36.
Van Klinken BJ, et al. Mucin gene construction and expression: safety vs adhesion. Am J Physiol-Gastrointest Liver Physiol. 1995;269(5):G613–27.
Neutra MR. Gastrointestinal mucus: synthesis, secretion, and performance. Physiol Gastrointest Tract. 1987:975–1009.
Moran AP, Gupta A, Joshi L. Candy-talk: function of host glycosylation in bacterial pathogenesis of the gastrointestinal tract. Intestine. 2011;60(10):1412–25.
Yudin AI, Hanson FW, Katz DF. Human cervical mucus and its interplay with sperm: a fine-structural view. Biol Reprod. 1989;40(3):661–71.
Olmsted SS, et al. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J. 2001;81(4):1930–7.
Bajka BH, et al. The affect of small intestinal mucus construction on particle transport ex vivo. Colloids Surf B. 2015;135:73–80.
Ensign LM, et al. Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues. Mol Pharm. 2013;10(6):2176–82.
Abdulkarim M, et al. Nanoparticle diffusion inside intestinal mucus: three-dimensional response evaluation dissecting the impression of particle floor cost, measurement and heterogeneity throughout polyelectrolyte, pegylated and viral particles. Eur J Pharm Biopharm. 2015;97:230–8.
Celli J, et al. Viscoelastic properties and dynamics of porcine gastric mucin. Biomacromol. 2005;6(3):1329–33.
Georgiades P, et al. Particle monitoring microrheology of purified gastrointestinal mucins. Biopolymers. 2014;101(4):366–77.
Yildiz HM, et al. Meals-associated stimuli improve barrier properties of gastrointestinal mucus. Biomaterials. 2015;54:1–8.
Sharma A, et al. In vitro reconstitution of an intestinal mucus layer exhibits that cations and pH management the pore construction that regulates its permeability and barrier operate. ACS Appl Bio Mater. 2020;3(5):2897–909.
Nhu NTQ, et al. Alkaline pH will increase swimming velocity and facilitates mucus penetration for Vibrio cholerae. J Bacteriol. 2021;203(7):e00607-20.
Yildiz HM, et al. Measurement selectivity of intestinal mucus to diffusing particulates depends on floor chemistry and publicity to lipids. J Drug Goal. 2015;23(7–8):768–74.
Mackie A, et al. Growing dietary oat fibre decreases the permeability of intestinal mucus. J Funct Meals. 2016;26:418–27.
Maisel Okay, et al. Impact of floor chemistry on nanoparticle interplay with gastrointestinal mucus and distribution within the gastrointestinal tract following oral and rectal administration within the mouse. J Management Launch. 2015;197:48–57.
Xu R-J. Growth of the new child GI tract and its relation to colostrum/milk consumption: a overview. Reprod Fertil Dev. 1996;8(1):35–48.
Farinati F, et al. Modifications in parietal and mucous cell mass within the gastric mucosa of regular topics with age: a morphometric research. Gerontology. 1993;39(3):146–51.
Corfield AP, et al. Sialic acids in human gastric aspirates: detection of 9-O-lactyl- and 9-O-acetyl-N-acetylneuraminic acids and a lower in complete sialic acid focus with age. Clin Sci (Lond). 1993;84(5):573–9.
Cryer B, et al. Impact of growing old on gastric and duodenal mucosal prostaglandin concentrations in people. Gastroenterology. 1992;102(4):1118–23.
Larhed AW, et al. Diffusion of medication in native and purified gastrointestinal mucus. J Pharm Sci. 1997;86(6):660–5.
Matthes I, et al. Mucus fashions for investigation of intestinal absorption mechanisms. 4. Comparability of mucus fashions with absorption fashions in vivo and in situ for prediction of intestinal drug absorption. Pharmazie. 1992;47(10):787–91.
Kas HS. Chitosan: properties, preparations and software to microparticulate methods. J Microencapsul. 1997;14(6):689–711.
Svensson O, Arnebrant T. Mucin layers and multilayers—physicochemical properties and purposes. Curr Opin Colloid Interface Sci. 2010;15(6):395–405.
Rubinstein A, Tirosh B. Mucus gel thickness and turnover within the gastrointestinal tract of the rat: response to cholinergic stimulus and implication for mucoadhesion. Pharm Res. 1994;11(6):794–9.
Navabi N, et al. Helicobacter pylori an infection impairs the mucin manufacturing price and turnover within the murine gastric mucosa. Infect Immun. 2013;81(3):829–37.
Johansson ME. Quick renewal of the distal colonic mucus layers by the floor goblet cells as measured by in vivo labeling of mucin glycoproteins. PLoS ONE. 2012;7(7):e41009.
Pothuraju R, et al. Mechanistic and purposeful shades of mucins and related glycans in colon most cancers. Cancers (Basel). 2020;12(3):649.
Clean M, et al. Expression of MUC2-mucin in colorectal adenomas and carcinomas of various histological sorts. Int J Most cancers. 1994;59(3):301–6.
Van der Sluis M, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is essential for colonic safety. Gastroenterology. 2006;131(1):117–29.
Martens EC, et al. Coordinate regulation of glycan degradation and polysaccharide capsule biosynthesis by a outstanding human intestine symbiont. J Biol Chem. 2009;284(27):18445–57.
Hollingsworth MA, Swanson BJ. Mucins in most cancers: safety and management of the cell floor. Nat Rev Most cancers. 2004;4(1):45–60.
Kim YS, Ho SB. Intestinal goblet cells and mucins in well being and illness: latest insights and progress. Curr Gastroenterol Rep. 2010;12(5):319–30.
Okudaira Okay, et al. MUC2 gene promoter methylation in mucinous and non-mucinous colorectal most cancers tissues. Int J Oncol. 2010;36(4):765–75.
Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal most cancers. Most cancers Metastasis Rev. 2004;23(1–2):77–99.
Johansson ME, et al. Micro organism penetrate the interior mucus layer earlier than irritation within the dextran sulfate colitis mannequin. PLoS ONE. 2010;5(8):e12238.
Sartor RB. Microbial influences in inflammatory bowel ailments. Gastroenterology. 2008;134(2):577–94.
Heazlewood CK, et al. Aberrant mucin meeting in mice causes endoplasmic reticulum stress and spontaneous irritation resembling ulcerative colitis. PLoS Med. 2008;5(3):e54.
Bergstrom Okay, et al. Core 1- and 3-derived O-glycans collectively preserve the colonic mucus barrier and defend in opposition to spontaneous colitis in mice. Mucosal Immunol. 2017;10(1):91–103.
Roy RK, et al. CEACAM6 is upregulated by Helicobacter pylori CagA and is a biomarker for early gastric most cancers. Oncotarget. 2016;7(34):55290–301.
Locker GY, et al. ASCO 2006 replace of suggestions for using tumor markers in gastrointestinal most cancers. J Clin Oncol. 2006;24(33):5313–27.
Comelli EM, et al. Biomarkers of human gastrointestinal tract areas. Mamm Genome. 2009;20(8):516–27.
Soendergaard C, et al. Alpha-1 antitrypsin and granulocyte colony-stimulating issue as serum biomarkers of illness severity in ulcerative colitis. Inflamm Bowel Dis. 2015;21(5):1077–88.
Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel illness. Infect Immun. 2000;68(12):7010–7.
Serada S, et al. Serum leucine-rich alpha-2 glycoprotein is a illness exercise biomarker in ulcerative colitis. Inflamm Bowel Dis. 2012;18(11):2169–79.
Juge N. Microbial adhesins to gastrointestinal mucus. Traits Microbiol. 2012;20(1):30–9.
Boekhorst J, et al. Comparative evaluation of proteins with a mucus-binding area discovered solely in lactic acid micro organism. Microbiology. 2006;152(Pt 1):273–80.
Miyoshi Y, et al. A mucus adhesion selling protein, MapA, mediates the adhesion of Lactobacillus reuteri to Caco-2 human intestinal epithelial cells. Biosci Biotechnol Biochem. 2006;70(7):1622–8.
Watanabe M, et al. An adhesin-like protein, Lam29, from Lactobacillus mucosae ME-340 binds to histone H3 and blood group antigens in human colonic mucus. Biosci Biotechnol Biochem. 2012;76(9):1655–60.
Van Tassell ML, Miller MJ. Lactobacillus adhesion to mucus. Vitamins. 2011;3(5):613–36.
Banla LI, et al. Sortase-dependent proteins promote gastrointestinal colonization by Enterococci. Infect Immun. 2019;87(5):e00853-18.
Erdem AL, et al. Host protein binding and adhesive properties of H6 and H7 flagella of attaching and effacing Escherichia coli. J Bacteriol. 2007;189(20):7426–35.
Sanchez B, et al. A flagellin-producing Lactococcus pressure: interactions with mucin and enteropathogens. FEMS Microbiol Lett. 2011;318(2):101–7.
Tasteyre A, et al. Function of FliC and FliD flagellar proteins of Clostridium difficile in adherence and intestine colonization. Infect Immun. 2001;69(12):7937–40.
Tu QV, McGuckin MA, Mendz GL. Campylobacter jejuni response to human mucin MUC2: modulation of colonization and pathogenicity determinants. J Med Microbiol. 2008;57(Pt 7):795–802.
Jin LZ, et al. Characterization and purification of porcine small intestinal mucus receptor for Escherichia coli K88ac fimbrial adhesin. FEMS Immunol Med Microbiol. 2000;27(1):17–22.
Chessa D, et al. RosE represses Std fimbrial expression in Salmonella enterica serotype Typhimurium. Mol Microbiol. 2008;68(3):573–87.
Kankainen M, et al. Comparative genomic evaluation of Lactobacillus rhamnosus GG reveals pili containing a human-mucus binding protein. Proc Natl Acad Sci USA. 2009;106(40):17193–8.
von Ossowski I, et al. Mucosal adhesion properties of the probiotic Lactobacillus rhamnosus GG SpaCBA and SpaFED pilin subunits. Appl Environ Microbiol. 2010;76(7):2049–57.
Geerlings SY, et al. Akkermansia muciniphila within the human gastrointestinal tract: when, the place, and the way? Microorganisms. 2018;6(3):75.
Martens EC, Chiang HC, Gordon JI. Mucosal glycan foraging enhances health and transmission of a saccharolytic human intestine bacterial symbiont. Cell Host Microbe. 2008;4(5):447–57.
Praharaj AB, et al. Molecular dynamics insights into the construction, operate, and substrate binding mechanism of mucin desulfating sulfatase of intestine microbe Bacteroides fragilis. J Cell Biochem. 2018;119(4):3618–31.
Lidell ME, et al. Entamoeba histolytica cysteine proteases cleave the MUC2 mucin in its C-terminal area and dissolve the protecting colonic mucus gel. Proc Natl Acad Sci USA. 2006;103(24):9298–303.
Akiyama Y, Nagahara N. Novel formulation approaches to oral mucoadhesive drug supply methods. Medication Pharm Sci. 1999;98:477–505.
Dhaliwal S, et al. Mucoadhesive microspheres for gastroretentive supply of acyclovir: in vitro and in vivo analysis. AAPS J. 2008;10(2):322–30.
Han HK, Shin HJ, Ha DH. Improved oral bioavailability of alendronate through the mucoadhesive liposomal supply system. Eur J Pharm Sci. 2012;46(5):500–7.
Manconi M, et al. Bettering oral bioavailability and pharmacokinetics of liposomal metformin by glycerolphosphate-chitosan microcomplexation. AAPS PharmSciTech. 2013;14(2):485–96.
Shin BS, et al. Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage type. Most cancers Chemother Pharmacol. 2009;64(1):87–94.
Cao QR, et al. Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan ready by a dry powder-coating approach. Int J Pharm. 2012;434(1–2):325–33.
Sensible JD. The fundamentals and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005;57(11):1556–68.
Durrer C, et al. Mucoadhesion of latexes. II. Adsorption isotherms and desorption research. Pharm Res. 1994;11(5):680–3.
Sensible JD. The function of water motion and polymer hydration in mucoadhesion. Medication Pharm Sci. 1999;98:11–23.
Mortazavi SA, Sensible JD. An investigation into the function of water motion and mucus gel dehydration in mucoadhesion. J Management Launch. 1993;25(3):197–203.
Silberberg-Bouhnik M, et al. Osmotic deswelling of weakly charged poly (acrylic acid) options and gels. J Polym Sci, Half B: Polym Phys. 1995;33(16):2269–79.
Voyutskii SS. Autohesion and adhesion of excessive polymers. New York: Interscience; 1963.
Peppas NA, Sahlin JJ. Hydrogels as mucoadhesive and bioadhesive supplies: a overview. Biomaterials. 1996;17(16):1553–61.
Mikos A, Peppas N. Scaling ideas and molecular theories of adhesion of artificial polymers to glycoproteinic networks. In: Bioadhesive drug supply methods. Boca Raton, FL: CRC Press; 1990. p. 25–42.
Peppas N, Mikos A. Kinetics of mucus-polymer interactions. Paperback APV. 1990;25:65–85.
Peppas NA. Molecular calculations of poly(ethylene glycol) transport throughout a swollen poly (acrylic acid)/mucin interface. J Biomater Sci Polym Ed. 1998;9(6):535–42.
Sahlin JJ, Peppas NA. An investigation of polymer diffusion in hydrogel laminates utilizing near-field FTIR microscopy. Macromolecules. 1996;29(22):7124–9.
Peppas NA, Thomas JB, McGinty J. Molecular features of mucoadhesive service improvement for drug supply and improved absorption. J Biomater Sci Polym Ed. 2009;20(1):1–20.
Edmans JG, et al. Mucoadhesive electrospun fibre-based applied sciences for oral drugs. Pharmaceutics. 2020;12(6):504.
Derjaguin BV, et al. On the connection between the electrostatic and the molecular element of the adhesion of elastic particles to a stable floor. J Colloid Interface Sci. 1977;58(3):528–33.
Sogias IA, Williams AC, Khutoryanskiy VV. Why is chitosan mucoadhesive? Biomacromol. 2008;9(7):1837–42.
Younes I, Rinaudo M. Chitin and chitosan preparation from marine sources. Construction, properties and purposes. Mar Medication. 2015;13(3):1133–74.
Bravo-Osuna I, et al. Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials. 2007;28(13):2233–43.
Alishahi A, et al. Shelf life and supply enhancement of vitamin C utilizing chitosan nanoparticles. Meals Chem. 2011;126(3):935–40.
Ling Tan JS, Roberts CJ, Billa N. Mucoadhesive chitosan-coated nanostructured lipid carriers for oral supply of amphotericin B. Pharm Dev Technol. 2019;24(4):504–12.
Imperiale JC, et al. Oral pharmacokinetics of a chitosan-based nano- drug supply system of interferon alpha. Polymers (Basel). 2019;11(11):1862.
Murthy A, et al. Self-assembled lecithin-chitosan nanoparticles enhance the oral bioavailability and alter the pharmacokinetics of raloxifene. Int J Pharm. 2020;588:119731.
Wang J, et al. Oral supply of metformin by chitosan nanoparticles for polycystic kidney illness. J Management Launch. 2020;329:1198–209.
Rosso A, et al. Nanocomposite sponges for enhancing intestinal residence time following oral administration. J Management Launch. 2021;333:579–92.
Shin GH, Kim JT. Comparative research of chitosan and oligochitosan coatings on mucoadhesion of curcumin nanosuspensions. Pharmaceutics. 2021;13(12):2154.
Cheng H, et al. Mucoadhesive versus mucopenetrating nanoparticles for oral supply of insulin. Acta Biomater. 2021;135:506–19.
Abd El Hady WE, et al. Glutaraldehyde-crosslinked chitosan-polyethylene oxide nanofibers as a possible gastroretentive supply system of nizatidine for augmented gastroprotective exercise. Drug Deliv. 2021;28(1):1795–809.
Kumar A, Vimal A. Why Chitosan? From properties to perspective of mucosal drug supply. Int J Biol Macromol. 2016;91:615–22.
George M, Abraham TE. Polyionic hydrocolloids for the intestinal supply of protein medication: alginate and chitosan—a overview. J Management Launch. 2006;114(1):1–14.
Sandri G, et al. Buccal penetration enhancement properties of N-trimethyl chitosan: affect of quaternization diploma on absorption of a excessive molecular weight molecule. Int J Pharm. 2005;297(1–2):146–55.
Ramalingam P, Ko YT. Improved oral supply of resveratrol from N-trimethyl chitosan-g-palmitic acid surface-modified stable lipid nanoparticles. Colloids Surf B Biointerfaces. 2016;139:52–61.
Leitner VM, Walker GF, Bernkop-Schnurch A. Thiolated polymers: proof for the formation of disulphide bonds with mucus glycoproteins. Eur J Pharm Biopharm. 2003;56(2):207–14.
Moghaddam FA, Atyabi F, Dinarvand R. Preparation and in vitro analysis of mucoadhesion and permeation enhancement of thiolated chitosan-pHEMA core-shell nanoparticles. Nanomedicine. 2009;5(2):208–15.
Dunnhaupt S, et al. Distribution of thiolated mucoadhesive nanoparticles on intestinal mucosa. Int J Pharm. 2011;408(1–2):191–9.
Millotti G, et al. In vivo analysis of thiolated chitosan tablets for oral insulin supply. J Pharm Sci. 2014;103(10):3165–70.
Maria S, et al. Synthesis and characterization of pre-activated thiolated chitosan nanoparticles for oral supply of octreotide. J Drug Deliv Sci Technol. 2020;58:101807.
Singla AK, Chawla M, Singh A. Potential purposes of carbomer in oral mucoadhesive managed drug supply system: a overview. Drug Dev Ind Pharm. 2000;26(9):913–24.
Brown HP. Carboxylic polymers. In: U.S.P. Workplace, editor. 1957; United States.
Yang X, et al. Immobilization of pseudorabies virus in porcine tracheal respiratory mucus revealed by single particle monitoring. PLoS ONE. 2012;7(12):e51054.
Sensible JD, Kellaway IW, Worthington HE. An in-vitro investigation of mucosa-adhesive supplies to be used in managed drug supply. J Pharm Pharmacol. 1984;36(5):295–9.
Bottenberg P, et al. Growth and testing of bioadhesive, fluoride-containing slow-release tablets for oral use. J Pharm Pharmacol. 1991;43(7):457–64.
French DL, Mauger JW. Analysis of the physicochemical properties and dissolution traits of mesalamine: relevance to managed intestinal drug supply. Pharm Res. 1993;10(9):1285–90.
Sarkar D, et al. Sustained launch gastroretentive pill of metformin hydrochloride primarily based on poly (acrylic acid)-grafted-gellan. Int J Biol Macromol. 2017;96:137–48.
Takeuchi H, et al. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness within the oral administration of calcitonin to rats. J Management Launch. 2003;86(2–3):235–42.
Naderkhani E, et al. Improved permeability of acyclovir: optimization of mucoadhesive liposomes utilizing the phospholipid vesicle-based permeation assay. J Pharm Sci. 2014;103(2):661–8.
Ahmad N, et al. Enhancement of oral insulin bioavailability: in vitro and in vivo evaluation of nanoporous stimuli-responsive hydrogel microparticles. Skilled Opin Drug Deliv. 2016;13(5):621–32.
Cevher E, et al. Analysis of mechanical and mucoadhesive properties of clomiphene citrate gel formulations containing carbomers and their thiolated derivatives. Drug Deliv. 2008;15(1):57–67.
Bonengel S, et al. Thiolated alkyl-modified carbomers: novel excipients for mucoadhesive emulsions. Eur J Pharm Sci. 2015;75:123–30.
Lamson NG, et al. Anionic nanoparticles allow the oral supply of proteins by enhancing intestinal permeability. Nat Biomed Eng. 2020;4(1):84–96.
Chickering DE, Mathiowitz E. Bioadhesive microspheres: I. A novel electrobalance-based technique to review adhesive interactions between particular person microspheres and intestinal mucosa. J Management Launch. 1995;34(3):251–62.
Wee S, Gombotz WR. Protein launch from alginate matrices. Adv Drug Deliv Rev. 1998;31(3):267–85.
Lengthy L, et al. Investigation of vitamin B12-modified amphiphilic sodium alginate derivatives for enhancing the oral supply efficacy of peptide medication. Int J Nanomed. 2019;14:7743–58.
Ghosal Okay, et al. Novel interpenetrating polymeric community primarily based microbeads for supply of poorly water soluble drug. J Polym Res. 2020;27(4):1–11.
Azad AK, et al. Electro-hydrodynamic assisted synthesis of lecithin-stabilized peppermint oil-loaded alginate microbeads for intestinal drug supply. Int J Biol Macromol. 2021;185:861–75.
Jindal AB, Wasnik MN, Nair HA. Synthesis of thiolated alginate and analysis of mucoadhesiveness, cytotoxicity and launch retardant properties. Indian J Pharm Sci. 2010;72(6):766–74.
Davidovich-Pinhas M, Harari O, Bianco-Peled H. Evaluating the mucoadhesive properties of drug supply methods primarily based on hydrated thiolated alginate. J Management Launch. 2009;136(1):38–44.
Bernkop-Schnurch A, Kast CE, Richter MF. Enchancment within the mucoadhesive properties of alginate by the covalent attachment of cysteine. J Management Launch. 2001;71(3):277–85.
Netsomboon Okay, Bernkop-Schnurch A. Mucoadhesive vs. mucopenetrating particulate drug supply. Eur J Pharm Biopharm. 2016;98:76–89.
Grabovac V, Guggi D, Bernkop-Schnurch A. Comparability of the mucoadhesive properties of varied polymers. Adv Drug Deliv Rev. 2005;57(11):1713–23.
Mortazavi SAR. Investigation of varied parameters influencing the period of mucoadhesion of some polymer containing discs. DARU J Pharm Sci. 2002;10(3):98–104.
Park H, Robinson JR. Mechanisms of mucoadhesion of poly(acrylic acid) hydrogels. Pharm Res. 1987;4(6):457–64.
Suwannateep N, et al. Mucoadhesive curcumin nanospheres: organic exercise, adhesion to abdomen mucosa and launch of curcumin into the circulation. J Management Launch. 2011;151(2):176–82.
Xiong W, et al. Enhancing the photostability and bioaccessibility of resveratrol utilizing ovalbumin-carboxymethylcellulose nanocomplexes and nanoparticles. Meals Funct. 2018;9(7):3788–97.
Gadalla HH, et al. Colon-targeting of progesterone utilizing hybrid polymeric microspheres improves its bioavailability and in vivo organic efficacy. Int J Pharm. 2020;577: 119070.
Kaur Okay, Kumar P, Kush P. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for protected and efficient remedy of fungal an infection. Biomed Pharmacother. 2020;128:110297.
Nair AB, et al. HPMC- and PLGA-based nanoparticles for the mucoadhesive supply of sitagliptin: optimization and in vivo analysis in rats. Supplies (Basel). 2019;12(24):4239.
Wooden KM, Stone GM, Peppas NA. Wheat germ agglutinin functionalized complexation hydrogels for oral insulin supply. Biomacromol. 2008;9(4):1293–8.
Catron ND, Lee H, Messersmith PB. Enhancement of poly(ethylene glycol) mucoadsorption by biomimetic finish group functionalization. Biointerphases. 2006;1(4):134–41.
Cheng H, et al. Design of self-polymerized insulin loaded poly(n-butylcyanoacrylate) nanoparticles for tunable oral supply. J Management Launch. 2020;321:641–53.
Amin MK, Boateng JS. Floor modification of cell composition of matter (MCM)-41 sort silica nanoparticles for potential oral mucosa vaccine supply. J Pharm Sci. 2020;109:2271–83.
Laha B, et al. Novel propyl karaya gum nanogels for bosentan: in vitro and in vivo drug supply efficiency. Colloids Surf B Biointerfaces. 2019;180:263–72.
Cheng Z, et al. Growth of keratin nanoparticles for managed gastric mucoadhesion and drug launch. J Nanobiotechnol. 2018;16(1):24.
Harloff-Helleberg S, et al. Exploring the mucoadhesive habits of sucrose acetate isobutyrate: a novel excipient for oral supply of biopharmaceuticals. Drug Deliv. 2019;26(1):532–41.
Zhao P, et al. Nanoparticle-assembled bioadhesive coacervate coating with extended gastrointestinal retention for inflammatory bowel illness remedy. Nat Commun. 2021;12(1):7162.
Walker D, et al. Enzymatically energetic biomimetic micropropellers for the penetration of mucin gels. Sci Adv. 2015;1(11):e1500501.
Choi H, et al. Bioinspired urease-powered micromotor as an energetic oral drug supply service in abdomen. Bioact Mater. 2022;9:54–62.
Yang Y, et al. Speedy transport of germ-mimetic nanoparticles with twin conformational polyethylene glycol chains in organic tissues. Sci Adv. 2020;6(6):eaay9937.
Wang Y, et al. Chiral mesoporous silica nano-screws as an environment friendly biomimetic oral drug supply platform via a number of topological mechanisms. Acta Pharm Sin B. 2021;12:1432–46.
Tang Y, et al. Nanoparticles focused in opposition to cryptococcal pneumonia by interactions between Chitosan and its peptide ligand. Nano Lett. 2018;18(10):6207–13.
Cai L, et al. Boston ivy-inspired disc-like adhesive microparticles for drug supply. Analysis (Wash D C). 2021;2021:9895674.
Chen W, et al. Dynamic omnidirectional adhesive microneedle system for oral macromolecular drug supply. Sci Adv. 2022;8(1):eabk1792.
Yang M, et al. Biodegradable nanoparticles composed fully of protected supplies that quickly penetrate human mucus. Angew Chem Int Ed Engl. 2011;50(11):2597–600.
Lai SK, et al. Speedy transport of enormous polymeric nanoparticles in recent undiluted human mucus. Proc Natl Acad Sci USA. 2007;104(5):1482–7.
Bourganis V, et al. On the synthesis of mucus permeating nanocarriers. Eur J Pharm Biopharm. 2015;97(Pt A):239–49.
Wang YY, et al. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “slip” via the human mucus barrier. Angew Chem Int Ed Engl. 2008;47(50):9726–9.
Mert O, et al. A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles. J Management Launch. 2012;157(3):455–60.
Maisel Okay, et al. Nanoparticles coated with excessive molecular weight PEG penetrate mucus and supply uniform vaginal and colorectal distribution in vivo. Nanomedicine. 2016;11(11):1337–43.
Xu Q, et al. Scalable technique to supply biodegradable nanoparticles that quickly penetrate human mucus. J Management Launch. 2013;170(2):279–86.
Reboredo C, et al. Preparation and analysis of PEG-coated zein nanoparticles for oral drug supply functions. Int J Pharm. 2021;597:120287.
Anderski J, et al. Mucus-penetrating nanoparticles: promising drug supply methods for the photodynamic remedy of intestinal most cancers. Eur J Pharm Biopharm. 2018;129:1–9.
Tan X, et al. Hydrophilic and electroneutral nanoparticles to beat mucus trapping and improve oral supply of insulin. Mol Pharm. 2020;17(9):3177–91.
Guo S, et al. Analysis on the destiny of polymeric nanoparticles within the technique of the intestinal absorption primarily based on mannequin nanoparticles with numerous traits: measurement, floor cost and pro-hydrophobics. J Nanobiotechnol. 2021;19(1):32.
Sato H, et al. Polymeric nanocarriers with mucus-diffusive and mucus-adhesive properties to regulate pharmacokinetic habits of orally dosed Cyclosporine A. J Pharm Sci. 2020;109(2):1079–85.
Warren MR, et al. Milk exosomes with enhanced mucus penetrability for oral supply of siRNA. Biomater Sci. 2020;9:4260–77.
Le Z, et al. Antioxidant enzymes sequestered inside lipid-polymer hybrid nanoparticles for the native remedy of inflammatory bowel illness. ACS Appl Mater Interfaces. 2021;13(47):55966–77.
Goto T, et al. Gastrointestinal transit and mucoadhesive traits of complexation hydrogels in rats. J Pharm Sci. 2006;95(2):462–9.
Puranik AS, et al. Synthesis and characterization of pH-responsive nanoscale hydrogels for oral supply of hydrophobic therapeutics. Eur J Pharm Biopharm. 2016;108:196–213.
Tang BC, et al. Biodegradable polymer nanoparticles that quickly penetrate the human mucus barrier. Proc Natl Acad Sci USA. 2009;106(46):19268–73.
Rowe RC, Sheskey PJ, Owen SC. Handbook of pharmaceutical excipients, vol. 6. London: Pharmaceutical Press; 2006.
Emanuele RM. FLOCOR: a brand new anti-adhesive, rheologic agent. Skilled Opin Investig Medication. 1998;7(7):1193–200.
Li X, et al. Novel mucus-penetrating liposomes as a possible oral drug supply system: preparation, in vitro characterization, and enhanced mobile uptake. Int J Nanomed. 2011;6:3151–62.
Chen D, et al. Comparative research of Pluronic((R)) F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats. Int J Pharm. 2013;449(1–2):1–9.
Fares AR, ElMeshad AN, Kassem MAA. Enhancement of dissolution and oral bioavailability of lacidipine through pluronic P123/F127 combined polymeric micelles: formulation, optimization utilizing central composite design and in vivo bioavailability research. Drug Deliv. 2018;25(1):132–42.
Huang Y, et al. Oral nanotherapeutics with enhanced mucus penetration and ROS-responsive drug launch capacities for supply of curcumin to colitis tissues. J Mater Chem B. 2021;9:1604–15.
Date AA, et al. Mucus-penetrating budesonide nanosuspension enema for native remedy of inflammatory bowel illness. Biomaterials. 2018;185:97–105.
Music W, et al. Enhanced digestion inhibition and mucus penetration of F127-modified self-nanoemulsions for improved oral supply. Asian J Pharm Sci. 2018;13(4):326–35.
Wada A, Nakamura H. Nature of the cost distribution in proteins. Nature. 1981;293(5835):757–8.
Michen B, Graule T. Isoelectric factors of viruses. J Appl Microbiol. 2010;109(2):388–97.
Pereira de Sousa I, et al. Mucus permeating carriers: formulation and characterization of extremely densely charged nanoparticles. Eur J Pharm Biopharm. 2015;97(Pt A):273–9.
Pereira de Sousa I, et al. Insulin loaded mucus permeating nanoparticles: addressing the floor traits as characteristic to enhance mucus permeation. Int J Pharm. 2016;500(1–2):236–44.
Wu J, et al. Biomimetic Viruslike and cost reversible nanoparticles to sequentially overcome mucus and epithelial boundaries for oral insulin supply. ACS Appl Mater Interfaces. 2018;10(12):9916–28.
Bao C, et al. Enhanced transport of form and rigidity-tuned α-lactalbumin nanotubes throughout intestinal mucus and mobile boundaries. Nano Lett. 2020;20(2):1352–61.
Cheng H, et al. Design of folic acid adorned virus-mimicking nanoparticles for enhanced oral insulin supply. Int J Pharm. 2021;596:120297.
Zhang Y, et al. Virus-mimicking mesoporous silica nanoparticles with an electrically impartial and hydrophilic floor to enhance the oral absorption of insulin by breaking via twin boundaries of the mucus layer and the intestinal epithelium. ACS Appl Mater Interfaces. 2021;13(15):18077–88.
Han X, et al. Zwitterionic micelles effectively ship oral insulin with out opening tight junctions. Nat Nanotechnol. 2020;15:605–14.
Gao Y, et al. Zwitterion-functionalized mesoporous silica nanoparticles for enhancing oral supply of protein medication by overcoming a number of gastrointestinal boundaries. J Colloid Interface Sci. 2021;582(Pt A):364–75.
Rao R, et al. Bioinspired zwitterionic polyphosphoester modified porous silicon nanoparticles for environment friendly oral insulin supply. Biomater Sci. 2021;9(3):685–99.
Biosca A, et al. Zwitterionic self-assembled nanoparticles as carriers for Plasmodium focusing on in malaria oral remedy. J Management Launch. 2021;331:364–75.
Hu S, et al. Zwitterionic polydopamine modified nanoparticles as an environment friendly nanoplatform to beat each the mucus and epithelial boundaries. Chem Eng J. 2022;428:132107.
Dunnhaupt S, et al. Nano-carrier methods: methods to beat the mucus gel barrier. Eur J Pharm Biopharm. 2015;96:447–53.
Rohrer J, et al. Mucus permeating thiolated self-emulsifying drug supply methods. Eur J Pharm Biopharm. 2016;98:90–7.
Sheffner AL. The discount in vitro in viscosity of mucoprotein options by a brand new mucolytic agent, N-acetyl-l-cysteine. Ann N Y Acad Sci. 1963;106:298–310.
Takatsuka S, et al. Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant. Eur J Pharm Biopharm. 2006;62(1):52–8.
Tian C, et al. N-acetyl-L-cysteine functionalized nanostructured lipid service for bettering oral bioavailability of curcumin: preparation, in vitro and in vivo evaluations. Drug Deliv. 2017;24(1):1605–16.
Samaridou E, et al. Enzyme-functionalized PLGA nanoparticles with enhanced mucus permeation price. Nano Life. 2014;4(04):1441013.
Müller C, et al. Preparation and characterization of mucus-penetrating papain/poly (acrylic acid) nanoparticles for oral drug supply purposes. J Nanopart Res. 2013;15(1):1353.
Pereira de Sousa I, et al. Nanoparticles adorned with proteolytic enzymes, a promising technique to beat the mucus barrier. Eur J Pharm Biopharm. 2015;97(Pt A):257–64.
Zafar H, et al. Design of enzyme adorned mucopermeating nanocarriers for eradication of H. pylori an infection. J Nanopart Res. 2020;22(1):1–21.
Efiana NA, et al. Improved intestinal mucus permeation of vancomycin through incorporation into nanocarrier containing papain-palmitate. J Pharm Sci. 2019;108(10):3329–39.
Razzaq S, et al. A multifunctional polymeric micelle for focused supply of paclitaxel by the inhibition of the P-glycoprotein transporters. Nanomaterials. 2021;11(11):2858.
Homayun B, Choi HJ. Halloysite nanotube-embedded microparticles for intestine-targeted co-delivery of biopharmaceuticals. Int J Pharm. 2020;579:119152.
MuGard (oral mucoadhesive) FDA Approval Historical past. mso-padding-alt:31.0pt 31.0pt 31.0pt 31.0pt mso-border-shadow:sure”> https://www.medication.com/historical past/mugard.html. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication – Sitavig. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=203791. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication—Oravig. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=BasicSearch.course of. Accessed on 6 Nov 2021
510(ok) Premarket Notification—ProctiGard. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K140558. Accessed on 6 Nov 2021
Orphan Drug Designations and Approvals—SP1049C. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=248107. Accessed on 6 Nov 2021
Drug Approval Package deal: Cetylev effervescent tablets for oral resolution, 500 mg and a pair of.5 grams (acetylcysteine). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207916_toc.cfm. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (Diphenoxylate Hydrochloride and Atropine Sulfate). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=085372. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (TARKA). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=020591. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (KADIAN). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=020616. Accessed on 6 Nov 2021
Drug Approval Package deal: Uroxatral (alfuzosin hydrochloride) prolonged launch tablets. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021287_uroxatral_toc.cfm. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (Okay-Tab). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=018279. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (Exalgo). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=021217. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (Lescol XL). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=021192. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (Mirapex). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=020667. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (Voltaren-XR). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=020254. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (Kapspargo Sprinkle). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=210428. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (Glumetza). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=021748. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (Razadyne ER). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=021615. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (Trokendi XR). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=201635. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (Wellbutrin XL). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=021515. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (Elepsia XR). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=204417. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication (Aciphex). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&varApplNo=020973. Accessed on 6 Nov 2021
U.S. FDA approves generic drug product containing Lubrizol’s Carbopol® Polymer (Carbomer Homopolymer). https://newscenter.lubrizol.com/news-releases/news-release-details/us-fda-approves-generic-drug-product-containing-lubrizols?ID=1745109&c=250972&p=irol-newsArticle. Accessed on 6 Nov 2021
Valeant and Progenics Announce FDA approves relistor tablets for the remedy of opioid-induced constipation in adults with persistent non-cancer ache. https://www.medication.com/newdrugs/valeant-progenics-announce-fda-approves-relistor-opioid-induced-constipation-adults-chronic-non-4411.html. Accessed on 6 Nov 2021
Medication@FDA: FDA-Permitted Medication—Meprom. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?occasion=overview.course of&ApplNo=020500. Accessed on 6 Nov 2021
Drug Approval Package deal—Malarone. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021078_malarone.cfm. Accessed on 6 Nov 2021
Eastwood GL. Gastrointestinal epithelial renewal. Gastroenterology. 1977;72(5, Half 1):962–75. Accessed on 6 Nov 2021
